Market Overview

VaxyGen Vaccines Ltd. Announces Exclusive Strategic Vaccine Collaboration with The Serum Institute of India (SII)


VaxyGen Vaccines Ltd. announced today the signing of a strategic collaboration agreement with the Serum Institute of India (SII). Under the terms of the agreement, VaxyGen Vaccines Ltd. will have exclusive rights to commercialize certain SII approved and pipeline products in North America and the European Union.

VaxyGen Vaccines Ltd. is a recently formed vaccine operating company, founded on the premise of ensuring affordable, innovative vaccines, contributing to 100% immunization of recommended vaccines achieved within its territories. SII is one of the world's largest suppliers of vaccines, reaching underserved populations in more than 140 countries. Two of every three children immunized worldwide receive at least one vaccine produced by SII.

“We are pleased to announce this groundbreaking agreement with the Serum Institute of India,” said David Dodd, CEO and Co-Founder of VaxyGen Holdings, LLC, the parent company of VaxyGen Vaccines, Ltd. “This agreement establishes VaxyGen Vaccines as a new operating competitor in the North American and EU vaccine markets, one that is primarily focused on seeing 100% immunization achieved through the delivery of affordable, innovative vaccines. We believe that competitive success, attractive return on investment and, most important, full immunization of recommended vaccines can be highly compatible goals and achievements.” It is estimated that the North American vaccine market exceeds $12.0 billion annually; the EU vaccine market is estimated at $6.5 billion.

“Our agreement with VaxyGen Vaccines is a major milestone for SII,” said Subhash Kapre, PhD., Executive Director, Serum Institute of India. “Although SII is one of the largest suppliers of vaccines worldwide, this agreement makes it possible, for the first time, to make our vaccines available to the North American and EU markets. It also supports our company's guiding principle: Progress is not only about how we grow. It is about how we make a difference in the lives of others.”

About VaxyGen Holdings, LLC

VaxyGen Holdings, LLC, is the parent company of three separate businesses:

  • VaxyGen Vaccines Ltd., focused on developing and commercializing vaccines, and committed to improving life through affordable, innovative vaccines;
  • VaxyGen Assay Services, LLC, providing contract, custom assay services in support of biopharmaceutical and vaccine companies, within a GLP facility;
  • VaxyGen Manufacturing Services, LLC, providing contract services in support of biological process optimization, scale-up, and the production of recombinant proteins and vaccines related to Phase I & II clinical programs within a GMP facility.

About Serum Institute of India (SII)

Serum Institute of India was founded in 1966 with the aim of manufacturing life-saving immuno-biologicals which, at that time, were in short supply in India and imported at high prices. Today, SII is recognized as the largest biotech company in India and the fifth largest vaccine manufacturer (by volume) in the world with an annual capacity of more than one billion doses of vaccines.

SII is the world's largest supplier of vaccines to more than 140 countries, and it is estimated that two of every three children immunized worldwide receives at least one vaccine produced by SII. SII collaborates with multiple international agencies including WHO, PATH, NIH, NVI/RIVM, and the FDA to develop and provide quality life-saving vaccines at affordable prices.

Additional information is available at

Parallax Communications Group
Scott Litherland, 317-335-7898
VaxyGen Holdings, LLC
Kathryn Gallagher, 843-576-9840

View Comments and Join the Discussion!
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at